25 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
pricing limitations may, therefore, hinder our ability to recoup our investment in one or more of our product candidates, even if our product candidates
ARS
i5uj1jp8szdv90o
28 Apr 23
Annual report to shareholders
7:03am
424B4
o6gr4 1gc
21 Jun 21
Prospectus supplement with pricing info
8:08am
DRS
nrp995cd
19 May 21
Draft registration statement
12:00am
10-K
g49bpyl wj
11 Mar 21
Annual report
4:19pm